ROR1 expression in chronic lymphocytic leukemia and the effect of CD5
1 Prince Mohammed hospital, Lab. & blood bank, Riyadh, Saudi Arabia, Arabian Gulf university, Manamah, Bahrain.
2 Saudi ministry of health, Riyadh, Saudi Arabia
Research Article
World Journal of Advanced Research and Reviews, 2020, 07(03), 091-095
Article DOI: 10.30574/wjarr.2020.7.3.0260
Publication history:
Received on 13 July 2020; revised on 17 August 2020; accepted on 20 August 2020
Abstract:
B cell chronic lymphocytic leukemia (CLL) is characterized by accumulation of monoclonal CD5+ mature B cells. The expression of CD5 plays a role in the malignant behavior of CLL cells via controlling the expression of some genes that enhance the expression of; apoptosis inhibitors BCL-2, NF-κB, Wnt, and cytokine. By being naturally phosphorylated on tyrosines, CD5 is chronically activated in CLL cells. Moreover, B CLL cell also characterized by the expression of ROR1. In this study we wanted to know if CD5 has an effect on the surface expression of ROR1 in CLL cells via comparing the mean fluorescence intensity (MFI) between CD5 and ROR1.Therefore, A cross-sectional study of immune-phenotype results for 50 randomly selected patients diagnosed with CLL in the period from June 2014 till Jan.2016 was performed. 28 cases were excluded because ROR1 test was not performed for them. The study was carried out on 22 patients. The correlation between CD5 MFI and ROR1 MFI was assessed using Spearman’s correlation. We found that in 21 out of 22 cases the correlation was significant with P < 0.001 and correlation coefficient (rs) of 0.788. This study gives us a hint that CD5 might have an effect on the expression of ROR1 in CLL lymphocytes. This finding needs to be supported by experimental study looking at the mechanism by which CD5 has such an effect.
Keywords:
ROR1; CD5; CLL; MFI
Full text article in PDF:
Copyright information:
Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0